The X linked condition of adrenoleucodystrophy/adrenomyeloneuropathy (ALD) is characterised by marked variability in clinical manifestation. The tant X and the normal X, such conclusions would be prone to error.
Results Three of the women tested were manifesting carriers and nine were free of symptoms and signs (table). Of the three manifesting carriers tested, only one (BII 1) showed skewedness with a ratio of 75:25; the other two, both of whom had a lower age of onset, had ratios of 60:40, (DI-2) and 55:45 (FIII-4) respectively (fig 2) . Of the nine non-manifesting carriers, skewed X inactivation of 75:25 or worse was shown by two, namely AIIM1 and EII1; three further women had ratios of 65:35.
Discussion
It is not yet clear what proportion of female carriers of ALD are symptomatic, since their presence in a pedigree increases the family's chances of being diagnosed or ascertained. All three manifesting carriers in our five families had presented to a neurologist independently of the illness in affected males, and in one of the three cases it was the presence of both a male with Addison's disease and his sister with a spastic paraplegia that led to the correct diganosis. Ignoring such biases in ascertainment, three of our nine carriers aged 40 or over had symptoms of ALD, while the remainder had no signs. However, had brain stem evoked responses been performed it is possible that we might have recognised abnormalities in some of the asymptomatic women. ' Densitometry proved useful in our investigations in giving an accurate and objective documentation of X inactivation. We considered that a ratio of 75:25 of the two X alleles indicated 'skewedness'. Unfortunately, it was not possible to identify whether the X chromosome bearing the mutant ALD allele was predominantly active or vice versa, since the ALD locus in Xq28 is far from the DXS255 locus in Xpl 1, and nine of the 12 fathers of carriers were dead. In family E, however, of the four non-manifesting carrier sisters, three had random X inactivation and the fourth had skewed inactivation favouring activity of the maternal X chromsome.
Our results on X inactivation patterns in female carriers show no association of skewed inactivation with manifestation, as only one of the three manifesting carriers showed skewing, and so did two of nine non-manifesting carriers. There was also no obvious association of skewing with age and no familial consistency of pattern, since in families A and B mothers with skewed patterns had daughters with random X inactivation. It has been suggested that these features indicate a lack of association between a specific mutation and the tendency to inactivate. '5 Despite the finding that some cases of female manifestation of certain severe X linked diseases could be attributed at least in part to the disease gene being over-represented on the active X chromosome,7'5 such events are usually driven by mechanisms such as X;autosome translocations,'6 X chromosome deletions, '7 or even twinning.'8 Indeed there is such marked selection in favour of cells carrying the non-mutant allele in active form in some forms of X linked immunological disease that it can be used to determine carrier status in unaffected females.579 '9 In female carriers of Alport's syndrome, however, no correlation between clinical manifestation and skewing of X inactivation could be detected.20 It may be that in some X linked diseases, such as ALD, extrapolation from fibroblasts or lymphocytes does not indicate the percentage of normal to mutant alleles present in more relevant tissues. The percentage of active mutation-bearing X chromosome homologues might be influenced by selection, although in one case of incontinentia pigmenti in a female both fibroblasts and lymphocytes showed a symmetrical inactivation pattern.'5 It is also not possible to determine the direction of skewing in the majority of our subjects as their parents are dead.
In the present study, there is a lack of any association between the pattern of X inactivation and clinical manifestation. We have to conclude that X inactivation patterns in DNA derived from white cells does not accord with clinical manifestation and that the other possible causes mentioned in the Introduction should be considered. If ALD is a dominant disorder, then FII-2 should be manifesting symptoms at her age of 76. However, she is not an obligatory heterozygote and could be an example of a gonadal (or gonosomal) mosaic, a situation which has been shown in another family2' where three unaffected males possessed the same allele at DXS52 as did their carrier sister and affected brother. Another possibility we considered is that the effect of the mutant allele is greater when transmitted from a father to his daughters, as in the two girls described by O'Neill et al,22 who developed spastic paraplegia in the first year of life. However, our patient BII 1, who inherited the mutant gene from her affected father did not develop symptoms until aged 58. The remaining three possibilities are those of secondary immunological phenomena, or of modification by autosomal genes, or of a gene that readily changes its structure and effect. This work is supported by a grant from Action Research. We are also grateful to Dr Yvonne Boyd for the gift of probe M27,B and for helpful discussion.
